About US
Contact us
-
EU revokes one of the patents on Biogen blockbuster TecfideraBiogen ($BIIB) has faced a number of challenges to its top-selling drug, multiple sclerosis medTecfidera, in the few years since it has been on the market. Now it faces a new one in Europe in the alwa2016/3/14
-
Ex-Sanofi, Schering CEOs were on a short list to replace Valeant chief Pearson: WSJPlenty of industry watchers didn't expect to see embattled Valeant ($VRX) CEO J. Michael Pearson return to the helm after a two-month bout with severe pneumonia. And as it turns out, he almost didn't.2016/3/14
-
Sanofi Pasteur and MSD to terminate vaccines JV in EuropeSanofi Pasteur and MSD, known as Merck in the US and Canada, are planning to terminate their joint venture (JV) that is involved in the development and commercialisation of vaccines in Europe. The JV2016/3/11
-
FDA approves Roche’s Gazyva to treat follicular lymphomaThe US Food and Drug Administration (FDA) has granted approval for Roche's approved Gazyva (obinutuzumab) plus bendamustine chemotherapy, followed by Gazyva alone as a new treatment for people with fo2016/3/11
-
Bristol-Myers scraps doc payments in China after last fall's FCPA settlementBristol-Myers Squibb ($BMY) is cracking down on its promotions inChina. According to multiple reports on news sites and social media, the company will stop paying speaker fees to doctors, curtail spen2016/3/10
-
AstraZeneca's Faslodex receives FDA approval for new indicationAstraZeneca has received approval from the US Food and Drug Administration (FDA) for a new indication of its Faslodex (fulvestrant) to treat women with hormone receptor-positive (HR+), human epidermal2016/3/10
-
With FDA settlement, tiny Amarin creates opening for pharma in off-label marketingMany of the Big Pharma players have paid hundreds of millions, sometimes billions, of dollars to settle federal litigation accusing them of pushing their products for unapproved uses. Now tiny Amarin2016/3/9
-
WHO recommends measures to prevent Zika virusThe World Health Organisation (WHO) has reported increasing evidence that the Zika virus is responsible for the cause of microcephaly and other neurological disorders. As a result, WHO has made certa2016/3/9
-
AstraZeneca to sell European rights of Moventig to ProStrakanAstraZeneca has agreed to sell the European rights for its peripherally-acting, mu-opioid receptor antagonist (PAMORA) Moventig to ProStrakan Group. Moventig is the first once-daily, oral Pamora appr2016/3/8
-
Teva Pharmaceutical acquires Mexico's Rimsa for $2.3bnTeva Pharmaceutical Industries has acquired a Mexican pharmaceutical manufacturing and distribution company Representaciones e Investigaciones Médicas (Rimsa) for $2.3bn. Plans for the deal were anno2016/3/8